A phase I clinical trial of flavone-8-acetic acid in combination with interleukin 2.
Holmund
J T
JT
Clinical Research Branch, National Cancer Institute-Frederick Cancer Research and Development Center, MD 21702, USA.
Kopp
W C
WC
Wiltrout
R H
RH
Longo
D L
DL
Urba
W J
WJ
Janik
J E
JE
Sznol
M
M
Conlon
K C
KC
Fenton
R G
RG
Hornung
R
R
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy / Q000556:secondary; D004334:Drug Administration Schedule; D005260:Female; D005419:Flavonoids / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D005419:Flavonoids; D007376:Interleukin-2; C049328:flavone acetic acid